Equity Method Investment (Notes)	12 Months Ended
Sep. 28, 2019
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	Investment in SuperSonic Imagine On August 1, 2019, the Company purchased 46% of the outstanding shares of SuperSonic Imagine ("SSI") for $18.2 million. SSI is a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares for a price of €1.50 per share in cash. The Company determined that SSI is a Variable Interest Entity (“VIE”) but it is not the primary beneficiary as it was not a party to the initial design of the entity nor does it have control over SSI's operations as of September 28, 2019. Accordingly, the Company accounted for this investment under the equity method of accounting and has included its proportionate share of SSI's net loss of $3.3 million for the two months ended September 28, 2019 within Other income, net. The fair value of the Company's investment in these shares at September 28, 2019 was $17.6 million. The Company has also provided loans totaling $28.4 million to SSI to pay-off certain of its preexisting loans and support its operating activities.

Equity Method Investment (Notes)

12 Months Ended

Sep. 28, 2019

Equity Method Investments and Joint Ventures [Abstract]

Investment in SuperSonic Imagine

On August 1, 2019, the Company purchased 46% of the outstanding shares of SuperSonic Imagine ("SSI") for $18.2 million. SSI is a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares for a price of €1.50 per share in cash. The Company determined that SSI is a Variable Interest Entity (“VIE”) but it is not the primary beneficiary as it was not a party to the initial design of the entity nor does it have control over SSI's operations as of September 28, 2019. Accordingly, the Company accounted for this investment under the equity method of accounting and has included its proportionate share of SSI's net loss of $3.3 million for the two months ended September 28, 2019 within Other income, net. The fair value of the Company's investment in these shares at September 28, 2019 was $17.6 million. The Company has also provided loans totaling $28.4 million to SSI to pay-off certain of its preexisting loans and support its operating activities.